Study: Late Start of COVID Treatment May Still Benefit Immunocompromised Patients
Study: Late Start of COVID Treatment May Still Benefit Immunocompromised Patients
Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, according to researchers in the Center for Translational Antiviral Research at Georgia State University’s Institute for Biomedical Sciences.